Amgen Inc. (4332.HK)
| Previous close | 1,850.000 |
| Open | 1,761.000 |
| Bid | 1,761.000 x N/A |
| Ask | 0.000 x N/A |
| Day's range | 1,761.000 - 1,761.000 |
| 52-week range | 1,761.000 - 1,850.000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.089T |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 16.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 66.66 (3.60%) |
| Ex-dividend date | 16 Nov 2023 |
| 1y target est | N/A |
- PR Newswire
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
- PR Newswire
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
- PR Newswire
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
